COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 12 FDA records to the applicant name Pramand, LLC. It includes 2 original PMA approvals. 8 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 6, 2023 to Oct 1, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NQR appears in 12 of the 12 linked filings. The collection spans 1 FDA product code and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P220014, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 201 Burlington Rd., Suite 210, Bedford, MA, 01730. Recorded on P220014/S013, decision dated Oct 1, 2026.
Device categories in this collection
Sealant, Dural.
Changes described in PMA records
FDA approved a revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS) for the CraniSeal Dural Sealant from Pramand, LLC. The supplement, identified as P220014/S013, was submitted to satisfy conditions of approval in the original P220014 approval order.
The decision is limited to the PAS protocol revision; it is not a new approval of the dural sealant device itself. The source statement does not describe what specific changes were made to the protocol, nor does it provide details about the study design, endpoints, or enrollment criteria. The device is categorized as a dural sealant under product code NQR.
FDA approval-order wording
Approval of the revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P220014.
Oct 1, 2026 · Normal 180 Day Track No User FeeThe FDA recorded approval of supplement P240027/S007 for SpineSeal™ Spine Sealant, sponsored by Pramand, LLC, on 2026-09-11. The supplement is classified as a real-time process change with the reason Change Design/Components/Specifications/Material. The recorded scope is a decrease in the lower specification limit for product swelling. This action amends the existing PMA rather than constituting a new approval of the whole sealant system.
The device falls under the dural sealant category, product code NQR, with neurology listed as the specialty. The source record does not include the prior specification value, the revised limit, supporting test data, or the supplement documents, so the magnitude and basis of the change remain unknown. No clinical or performance conclusions about the product follow from this record alone.
FDA approval-order wording
Approval to decrease the lower specification limit for product swelling.
Sep 11, 2026 · Real-Time ProcessFDA’s recorded scope: Approval for changes to the device packaging configuration to accommodate previously approved changes to the syringe accessory.
Aug 31, 2026 · Real-Time ProcessFDA’s recorded scope: Approval for a modification to the shelf-life protocol to incorporate use of accelerated aged samples followed by confirmation with real-time aged samples.
Aug 5, 2026 · Real-Time ProcessFDA’s recorded scope: a change to remove visible particulates prior to final packaging
Apr 1, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.